Form 4 Filing for Acrivon Therapeutics, Inc.

This filing reports on a transaction by Erick Gamelin, Chief Development Officer of Acrivon Therapeutics, Inc. On May 18, 2026, Gamelin acquired 38,584 shares of Common Stock via restricted stock units (RSUs) with a transaction price of $0.00. These RSUs vest over time, with 16.67% vesting on November 18, 2026, and the remainder vesting in subsequent quarterly installments, contingent on continued service. Following this transaction, Gamelin owns 52,992 shares of Common Stock.